BioLineRX
BLRX
28 hedge funds and large institutions have $13.5M invested in BioLineRX in 2021 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 10 increasing their positions, 2 reducing their positions, and 3 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 2
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
192% more capital invested
Capital invested by funds: $4.6M → $13.5M (+$8.85M)
33% more funds holding
Funds holding: 21 → 28 (+7)
0.02% more ownership
Funds ownership: 0.01% → 0.03% (+0.02%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
+$8.24M |
| 2 |
Renaissance Technologies
New York
|
+$716K |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$601K |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$123K |
| 5 |
IP
Intellectus Partners
San Francisco,
California
|
+$122K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$124K |
| 3 |
TNB
Thomasville National Bank
Thomasville,
Georgia
|
-$51K |
| 4 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$1.56K |
| 5 |
SFS
Sowell Financial Services
North Little Rock,
Arkansas
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Osaic Holdings
Scottsdale,
Arizona
| $2K | +$2.29K | +19 | +633% |
|
27
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $1K | +$962 | +8 | New |
|
|
RE
28
RBC Europe
London,
United Kingdom
| $36 | – | – | – |
|
|
29
Citadel Advisors
Miami,
Florida
| – | -$124K | -1,233 | Closed |
|
|
TNB
30
Thomasville National Bank
Thomasville,
Georgia
| – | -$51K | -508 | Closed |
|
|
SFS
31
Sowell Financial Services
North Little Rock,
Arkansas
| – | -$1K | -5 | Closed |
|
BLRX Hedge Fund Activity: Q1 2021 in Review
28 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q1 2021, worth a combined $13.5M — up 192% from $4.6M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new BLRX positions and 3 closed out — a net gain of 7 holders — while 10 added to existing stakes and 2 trimmed.
The largest buyer was Sio Capital Management, opening a new position worth an estimated $8.24M. The largest seller was Morgan Stanley, cutting an estimated $1M.
- 28 institutional investors held BioLineRX (BLRX) as of Q1 2021, up from 21 in Q4 2020.
- Funds reported $13.5M of BioLineRX stock for Q1 2021, up 192% quarter-over-quarter.
- 10 funds opened new BioLineRX positions in Q1 2021 and 3 closed out, a net change of +7 holders.
- The largest BioLineRX buyer in Q1 2021 was Sio Capital Management, an estimated $8.24M added.
- The largest BioLineRX seller in Q1 2021 was Morgan Stanley, an estimated $1M sold.
Based on aggregated 13F filings for Q1 2021.